Sigma Healthcare (ASX:SIG) has upgraded its full-year normalised EBIT guidance for the fiscal year ended Jan. 31.
The company now projects EBIT in the range of $64 to $70 million, an increase from the previous guidance of $50 to $60 million announced in September 2024.
The upward revision in guidance is attributed to improved operational performance, particularly the execution of a new supply contract with Chemist Warehouse.
The contract commenced on July 1, 2024, and has enabled Sigma to demonstrate its capacity to efficiently manage increased volume growth.
However, Sigma has indicated that the statutory net profit after tax for FY25 will be adversely affected by non-recurring merger-related costs.
These include changes to existing performance rights as approved at the Sigma extraordinary general meeting.
Sigma Healthcare's audited financial results are expected to be released to the Australian Securities Exchange in mid-March.
At the time of reporting, Sigma Healthcare's share price was $2.94.